Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
AssigneeCuRNA, Inc.
InventorsJoseph Collard, Olga Khorkova Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of NANOG, in particular, by targeting natural antisense polynucleotides of NANOG. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NANOG.
Claims16
A pharmaceutical composition comprising a synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
- at least one modified internucleotide linkage;
- at least one modified nucleotide, and combinations thereof;
- wherein said oligonucleotide is a single-stranded antisense compound which specifically hybridizes to a target region of a natural antisense polynucleotide of a NANOG gene having SEQ ID NO:
- 2 and is at least 90% complementary to said natural antisense polynucleotide and upregulates the function and/or expression of an NANOG gene in vivo or in vitro as compared to a normal control and a pharmaceutically acceptable excipient.
An oligonucleotide which comprises the sequences set forth as SEQ ID NOS:
- 3 to 5.
Dependencies are inferred from the claim text.